-
Founded in:
2003-04-30 -
Country:
China -
Address:
No. 518, Yunhe Road, Xinbei District, Changzhou -
Tax NO.:
91320400748726864T -
Registered Funds:
1,279.8 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Coenzyme A |
A coenzyme for acetylation reactions in the body. It participates in acetylation reactions in the body and plays an important role in the metabolism of sugar, fat and protein, such as the tricarboxylic acid cycle, liver glycogen storage, acetylcholine synthesis, lowering cholesterol, regulating blood lipid content and synthesizing steroid substances.
More
A coenzyme for acetylation reactions in the body. It participates in acetylation reactions in the body and plays an important role in the metabolism of sugar, fat and protein, such as the tricarboxylic acid cycle, liver glycogen storage, acetylcholine synthesis, lowering cholesterol, regulating blood lipid content and synthesizing steroid substances. |
85-61-0 | 4 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Coenzyme A |
A coenzyme for acetylation reactions in the body. It participates in acetylation reactions in the body and plays an important role in the metabolism of sugar, fat and protein, such as the tricarboxylic acid cycle, liver glycogen storage, acetylcholine synthesis, lowering cholesterol, regulating blood lipid content and synthesizing steroid substances.
More
A coenzyme for acetylation reactions in the body. It participates in acetylation reactions in the body and plays an important role in the metabolism of sugar, fat and protein, such as the tricarboxylic acid cycle, liver glycogen storage, acetylcholine synthesis, lowering cholesterol, regulating blood lipid content and synthesizing steroid substances. |
85-61-0 | 4 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ursodeoxycholic acid |
By inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into the bile, the saturation of cholesterol in the bile is reduced. Cholesterol stones may be gradually dissolved due to the dispersion of cholesterol and the formation of liquid crystals. The treatment of liver and cholestatic diseases is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation.
More
By inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into the bile, the saturation of cholesterol in the bile is reduced. Cholesterol stones may be gradually dissolved due to the dispersion of cholesterol and the formation of liquid crystals. The treatment of liver and cholestatic diseases is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation. |
128-13-2 | 40 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Heparin sodium |
Because this product has the physical and chemical characteristics of strong negative charge, it can interfere with many links of the blood coagulation process and has anticoagulant effect in vivo and in vitro. Its mechanism of action is relatively complex, mainly through binding with antithrombin III (AT-III), thereby enhancing the latter's inhibitory effect on activated coagulation factors II, IX, X, XI and XII. Its consequences involve preventing platelet aggregation and destruction, hindering the formation of coagulation activating enzymes; preventing prothrombin from turning into thrombin; inhibiting thrombin, thereby preventing fibrinogen from turning into fibrin.
More
Because this product has the physical and chemical characteristics of strong negative charge, it can interfere with many links of the blood coagulation process and has anticoagulant effect in vivo and in vitro. Its mechanism of action is relatively complex, mainly through binding with antithrombin III (AT-III), thereby enhancing the latter's inhibitory effect on activated coagulation factors II, IX, X, XI and XII. Its consequences involve preventing platelet aggregation and destruction, hindering the formation of coagulation activating enzymes; preventing prothrombin from turning into thrombin; inhibiting thrombin, thereby preventing fibrinogen from turning into fibrin. |
9041-08-1 | 83 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pancreatin |
Contains pancreatic lipase, pancreatic amylase, and trypsin, which can break down fat into glycerol and fatty acids, convert starch into sugar, and convert protein into peptone
More
Contains pancreatic lipase, pancreatic amylase, and trypsin, which can break down fat into glycerol and fatty acids, convert starch into sugar, and convert protein into peptone |
300mg | 8049-47-6 | 27 |
| Pepsin |
Can convert protein into albumen and peptone
More
Can convert protein into albumen and peptone |
13mg | 9001-75-6 | 21 |